CTOs on the Move

Daiichi Sankyo

www.daiichisankyo.com

 
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.
  • Number of Employees: 10K-50K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Tekmira Pharmaceuticals Corporation

Tekmira Pharmaceuticals Corporation is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NanoString

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research. The company`s technology enables a wide variety of basic research and translational medicine applications. NanoString`s products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection. In 2019, the company launched the GeoMx™ Digital Spatial Profiler enabling highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

Pharmaceutical Product Development

The Pharmaceutical Product Development, LLC is a global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services.

CordenPharma

CordenPharma is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

True North Therapeutics

True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The companys lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis. True North is currently focused on Complement-mediated rare diseases in the hematologic, renal, and neurological space. True North was formed in 2013 as a spin-out of iPierian.